Peptides vs SARMs: Mechanisms, Evidence & Legal Status

Peptides and SARMs are often lumped together as "performance compounds," but they are different kinds of molecules with different legal positions. SARMs (selective androgen receptor modulators) are small, non-steroidal molecules that bind the androgen receptor; none is FDA-approved, FDA says they are not dietary supplements, and WADA bans them at all times. "Peptides" is a broad chemical category — short chains of amino acids — that includes dozens of FDA-approved drugs as well as unapproved and research-only compounds, so their status has to be judged one peptide at a time.

Educational content for licensed healthcare professionals. Not medical advice; dosing and treatment decisions belong to the prescribing clinician.

Peptides vs SARMs at a Glance

What SARMs Are

Testosterone and dihydrotestosterone act on the androgen receptor (AR) in muscle, bone, prostate, skin and brain. SARMs were designed to activate the AR in muscle and bone while having less effect on the prostate and other tissues, avoiding some limitations of steroidal androgens [1]. Examples include enobosarm (ostarine), LGD-4033 (ligandrol), andarine and RAD140. They are small molecules, not peptides. Our LGD-4033 page covers one of them in detail.

Clinical development has produced real but limited data. In a randomized phase 2 trial in patients with cancer-related weight loss, enobosarm increased lean body mass compared with baseline [2]. In a 21-day placebo-controlled study in healthy young men, LGD-4033 increased lean body mass but also suppressed total testosterone, SHBG, HDL cholesterol and triglycerides; values returned to baseline after stopping [3]. A 2023 review describes SARMs as still being developed as function-promoting therapies for limitations associated with aging and chronic disease [4] — none has reached FDA approval.

What "Peptides" Covers

"Peptide" describes structure, not a drug class. More than 80 peptide drugs have reached the market worldwide [5]. In the U.S. alone, approved peptides include GLP-1 and dual-incretin agonists for diabetes and obesity, tesamorelin for HIV-associated abdominal fat, and bremelanotide for hypoactive sexual desire disorder. Alongside them sits a much larger group of unapproved peptides — BPC-157, TB-500, CJC-1295, ipamorelin and others — with mostly preclinical evidence. A useful primer is what are peptides.

Two consequences follow. First, a statement like "peptides are safer than SARMs" is not meaningful without naming the peptide: an approved GLP-1 drug and a research-only repair peptide have nothing in common in their evidence base. Second, not everything marketed alongside peptides is a peptide: MK-677 (ibutamoren), often sold as a "GH peptide," is an orally active small molecule, and it is in FDA's 503A Category 2 for significant safety risks (FDA's 503A bulk drug substance categories).

How the Mechanisms Differ

• Direct vs upstream action. SARMs bind the androgen receptor directly, the same receptor testosterone uses. Most performance-marketed peptides act upstream — for example, GH secretagogues stimulate the pituitary to release growth hormone, which is still subject to feedback. See growth hormone peptides for fat loss for that axis.
• Axis suppression. Because SARMs act on the AR, they suppress the hypothalamic-pituitary-gonadal axis; the LGD-4033 trial documented falls in total testosterone and SHBG even over three weeks [3].
• Lipids and liver. HDL reduction is a recurring finding with SARMs [3]. Liver injury has been reported repeatedly: an Australian series of 23 drug-induced liver injury cases linked to anabolic steroids, SARMs and bodybuilding supplements involved 14 SARMs, most patients were hospitalized, and one required a liver transplant [6].

Product Quality: The Shared Problem

Both categories share one practical risk — unregulated supply. When researchers bought 44 products marketed as SARMs online and analyzed them, only 52% contained a SARM; 39% contained another unapproved drug such as ibutamoren, GW501516 or SR9009; 25% contained substances not on the label; and only 41% contained the labeled amount [7]. Research-labeled peptides raise the same concerns, which is why FDA has issued warning letters to "research use only" peptide sellers. For prescribers, the safeguard is the same: approved products, or compounded preparations from licensed pharmacies using qualifying bulk substances.

Legal Status in 2026

SARMs. FDA states that SARM products "have not been approved by the FDA," that "they are not dietary supplements," and that they are "unapproved drugs that FDA has not reviewed for safety and effectiveness." Its consumer warning lists increased risk of heart attack or stroke, psychosis and hallucinations, liver injury and acute liver failure, infertility and testicular shrinkage among the potential harms (FDA). WADA prohibits SARMs at all times under S1.2 (USADA).

Peptides. Status depends on the peptide. Approved peptides are prescription drugs. Some unapproved peptides may be compounded by 503A pharmacies if the bulk substance qualifies; in July 2026 FDA's advisory committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon for the 503A Bulks List, but the votes are advisory and none is listed until FDA completes rulemaking. Check the FDA Peptide Status Tracker for any specific compound, and see FDA-legal peptides for the broader framework. Many peptides are also on the WADA Prohibited List.

Choosing Between Them Is Usually the Wrong Question

Patients often arrive asking "peptides or SARMs?" for muscle or body composition. The clinically useful reframing is: what is the goal, and is there an approved therapy with evidence for it? For diagnosed hypogonadism, approved testosterone therapy has a defined evidence base; for obesity, approved peptide drugs do. SARMs offer no approved option. Unapproved peptides sit in between — some have a compounding pathway and a regulatory review underway, most have limited human data. Our peptides for muscle growth hub sets out what is known for that goal.

Newtropin does not prescribe, compound, or dispense. We connect licensed providers with licensed 503A partner pharmacies that together cover all 50 states and D.C.; prescribers can start at For Providers.

Frequently Asked Questions

What is the difference between peptides and SARMs?

Peptides are chains of amino acids that act on many different receptors; SARMs are non-steroidal small molecules that act on the androgen receptor. Many peptides are FDA-approved drugs, while no SARM is approved.

Are SARMs legal?

SARMs are not FDA-approved, and FDA says they cannot be sold as dietary supplements; it treats them as unapproved drugs. WADA prohibits all SARMs at all times. Selling them for human consumption violates federal law.

Are peptides safer than SARMs?

It depends entirely on the peptide. Approved peptides have established safety profiles from large trials; many unapproved peptides have little human safety data. SARMs have documented risks including HDL reduction, testosterone suppression and liver injury.

Is MK-677 a peptide or a SARM?

Neither. MK-677 (ibutamoren) is a small-molecule growth hormone secretagogue that acts on the ghrelin receptor. It is often sold alongside peptides, and FDA lists it in 503A Category 2 for significant safety risks.

Do SARMs show up on drug tests?

Yes. Anti-doping laboratories test for SARMs and WADA prohibits them at all times. Contaminated or mislabeled products can also contain SARMs that are not listed on the label.

Can a doctor prescribe SARMs?

No SARM is FDA-approved, so there is no approved product to prescribe, and FDA considers SARM products unapproved drugs. Some SARMs have been studied in clinical trials, which is the only sanctioned setting for their use.

References

1. Narayanan R, et al. Development of selective androgen receptor modulators (SARMs). Mol Cell Endocrinol. 2018;465:134-142. PubMed
2. Dobs AS, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol. 2013;14(4):335-45. PubMed
3. Basaria S, et al. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. J Gerontol A Biol Sci Med Sci. 2013;68(1):87-95. PubMed
4. Bhasin S, et al. Androgens and Selective Androgen Receptor Modulators to Treat Functional Limitations Associated With Aging and Chronic Disease. J Gerontol A Biol Sci Med Sci. 2023;78(Suppl 1):25-31. PubMed
5. Muttenthaler M, et al. Trends in peptide drug discovery. Nat Rev Drug Discov. 2021;20(4):309-325. PubMed
6. Nash E, et al. Drug-induced liver injury from selective androgen receptor modulators, anabolic-androgenic steroids and bodybuilding supplements in Australia. Aliment Pharmacol Ther. 2024;59(8):953-961. PubMed
7. Van Wagoner RM, et al. Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet. JAMA. 2017;318(20):2004-2010. PubMed